Maria Laura Bolognesi

List of Publications by Citations

Source: https://exaly.com/author-pdf/3012677/maria-laura-bolognesi-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

171 papers	7,395 citations	46 h-index	80 g-index
198 ext. papers	8,376 ext. citations	6.1 avg, IF	6.1 L-index

#	Paper	IF	Citations
171	Multi-target-directed ligands to combat neurodegenerative diseases. *Journal of Medicinal Chemistry*, **2008**, 51, 347-72	8.3	816
170	A perspective on multi-target drug discovery and design for complex diseases. *Clinical and Translational Medicine*, **2018**, 7, 3	5.7	307
169	Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. *ChemBioChem*, **2007**, 8, 2152-61	3.8	289
168	Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. *Journal of Medicinal Chemistry*, **2007**, 50, 6446-9	8.3	225
167	Rational approach to discover multipotent anti-Alzheimer drugs. *Journal of Medicinal Chemistry*, **2005**, 48, 360-3	8.3	206
166	Tacrine derivatives and Alzheimer's disease. *Current Medicinal Chemistry*, **2010**, 17, 1825-38	4.3	180
165	Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania. *Journal of Medicinal Chemistry*, **2009**, 52, 7339-59	8.3	179
164	Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush. *Journal of Medicinal Chemistry*, **2008**, 51, 4381-4	8.3	170
163	A small molecule targeting the multifactorial nature of Alzheimer's disease. *Angewandte Chemie - International Edition*, **2007**, 46, 3689-92	16.4	156
162	Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation. *Journal of Medicinal Chemistry*, **2005**, 48, 24-7	8.3	127
161	Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects. *Journal of Medicinal Chemistry*, **2014**, 57, 8576-89	8.3	122
160	Imaging of β-amyloid plaques by near infrared fluorescent tracers: a new frontier for chemical neuroscience. *Chemical Society Reviews*, **2015**, 44, 1807-19	58.5	116
159	Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. *Journal of Medicinal Chemistry*, **2007**, 50, 4882-97	8.3	113
158	The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. *Journal of Medicinal Chemistry*, **2015**, 58, 4857-73	8.3	109
157	Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. *Journal of Medicinal Chemistry*, **2004**, 47, 5945-52	8.3	108
156	Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. *Neurotherapeutics*, **2009**, 6, 152-62	6.4	101
155	Alzheimer's disease: new approaches to drug discovery. *Current Opinion in Chemical Biology*, **2009**, 13, 303-8	9.7	100

154	Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3β inhibitors. *Angewandte Chemie - International Edition*, **2015**, 54, 1578-82	16.4	87
153	Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases. *Current Topics in Medicinal Chemistry*, **2019**, 19, 1694-1711	3	76
152	Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2017**, 127, 250-262	6.8	74
151	Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. *Journal of Medicinal Chemistry*, **1998**, 41, 4186-9	8.3	73
150	Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2011**, 46, 5435-42	6.8	71
149	Multifunctional tacrine derivatives in Alzheimer's disease. *Current Topics in Medicinal Chemistry*, **2013**, 13, 1771-86	3	71
148	Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment. *Neuropharmacology*, **2012**, 62, 997-1003	5.5	70
147	Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects. *Journal of Medicinal Chemistry*, **2006**, 49, 6642-5	8.3	70
146	Synthesis of a small library of 2-phenoxy-1,4-naphthoquinone and 2-phenoxy-1,4-anthraquinone derivatives bearing anti-trypanosomal and anti-leishmanial activity. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 2272-6	2.9	69
145	BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer's Disease. *Journal of Medicinal Chemistry*, **2018**, 61, 619-637	8.3	66
144	Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2016**, 108, 687-700	6.8	66
143	MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond. *Current Pharmaceutical Design*, **2009**, 15, 601-13	3.3	64
142	Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer's Disease. *Molecules*, **2016**, 21, 466	4.8	64
141	The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases. *Expert Opinion on Drug Discovery*, **2011**, 6, 251-68	6.2	63
140	Prejunctional muscarinic inhibitory control of acetylcholine release in the human isolated detrusor: involvement of the M4 receptor subtype. *British Journal of Pharmacology*, **2000**, 129, 493-500	8.6	63
139	Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. *Journal of Medicinal Chemistry*, **2009**, 52, 7883-6	8.3	62
138	Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer's disease. *PLoS ONE*, **2013**, 8, e56870	3.7	62
137	Novel 8-Hydroxyquinoline Derivatives as Multitarget Compounds for the Treatment of Alzheimer's Disease. *ChemMedChem*, **2016**, 11, 1284-95	3.7	59

136	Novel tacrine-grafted Ugi adducts as multipotent anti-Alzheimer drugs: a synthetic renewal in tacrine-ferulic acid hybrids. *ChemMedChem*, **2015**, 10, 523-39	3.7	56
135	Two diseases, one approach: multitarget drug discovery in Alzheimer's and neglected tropical diseases. *MedChemComm*, **2014**, 5, 853-861	5	56
134	Multitargeted drugs discovery: balancing anti-amyloid and anticholinesterase capacity in a single chemical entity. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2655-8	2.9	55
133	Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3 and Tau-Aggregation Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 7640-7656	8.3	53
132	Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer. *Journal of Medicinal Chemistry*, **2008**, 51, 7308-12	8.3	52
131	Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2019**, 168, 491-514	6.8	49
130	From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease. *Mini-Reviews in Medicinal Chemistry*, **2008**, 8, 960-7	3.2	48
129	3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3 Fragment Hits against Alzheimer's Disease. *ACS Chemical Neuroscience*, **2015**, 6, 1665-82	5.7	47
128	Naphthoquinone derivatives exert their antitrypanosomal activity via a multi-target mechanism. *PLoS Neglected Tropical Diseases*, **2013**, 7, e2012	4.8	46
127	Polyamines in drug discovery: from the universal template approach to the multitarget-directed ligand design strategy. *Journal of Medicinal Chemistry*, **2010**, 53, 5906-14	8.3	44
126	Binding profile of the selective muscarinic receptor antagonist tripitramine. *European Journal of Pharmacology*, **1994**, 268, 459-62		44
125	From combinations to multitarget-directed ligands: A continuum in Alzheimer's disease polypharmacology. *Medicinal Research Reviews*, **2021**, 41, 2606-2633	14.4	41
124	Prazosin-related compounds. Effect of transforming the piperazinylquinazoline moiety into an aminomethyltetrahydroacridine system on the affinity for alpha1-adrenoreceptors. *Journal of Medicinal Chemistry*, **2003**, 46, 4895-903	8.3	41
123	Synthesis and biological activity of some methoctramine-related tetraamines bearing a 11-acetyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]-benzodiazepin-6-one moiety as antimuscarinics: a second generation of highly selective M2 muscarinic receptor antagonists. *Journal of Medicinal Chemistry*, **1993**, 36, 3734-7	8.3	41
122	Changing paradigm to target microglia in neurodegenerative diseases: from anti-inflammatory strategy to active immunomodulation. *Expert Opinion on Therapeutic Targets*, **2016**, 20, 627-40	6.4	40
121	Recent advances in alpha1-adrenoreceptor antagonists as pharmacological tools and therapeutic agents. *Current Topics in Medicinal Chemistry*, **2007**, 7, 147-62	3	40
120	Toward the development of dual-targeted glyceraldehyde-3-phosphate dehydrogenase/trypanothione reductase inhibitors against Trypanosoma brucei and Trypanosoma cruzi. *ChemMedChem*, **2014**, 9, 371-82	3.7	39
119	New tacrine dimers with antioxidant linkers as dual drugs: Anti-Alzheimer's and antiproliferative agents. *European Journal of Medicinal Chemistry*, **2017**, 138, 761-773	6.8	38

118	Design, synthesis, and biological evaluation of symmetrically and unsymmetrically substituted methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. *Journal of Medicinal Chemistry*, **1999**, 42, 5212-23	8.3	37
117	A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimer's and Prion Diseases. *ACS Medicinal Chemistry Letters*, **2013**, 4, 225-9	4.3	36
116	2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile. *Journal of Medicinal Chemistry*, **2015**, 58, 6422-34	8.3	35
115	Bis(7)-tacrine derivatives as multitarget-directed ligands: Focus on anticholinesterase and antiamyloid activities. *ChemMedChem*, **2010**, 5, 1215-20	3.7	35
114	Privileged structure-guided synthesis of quinazoline derivatives as inhibitors of trypanothione reductase. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 3031-5	2.9	34
113	Discovery of a class of diketopiperazines as antiprion compounds. *ChemMedChem*, **2010**, 5, 1324-34	3.7	34
112	Polyamine conjugation of curcumin analogues toward the discovery of mitochondria-directed neuroprotective agents. *Journal of Medicinal Chemistry*, **2010**, 53, 7264-8	8.3	32
111	Lipoic acid, a lead structure for multi-target-directed drugs for neurodegeneration. *Mini-Reviews in Medicinal Chemistry*, **2006**, 6, 1269-74	3.2	32
110	Universal template approach to drug design: polyamines as selective muscarinic receptor antagonists. *Journal of Medicinal Chemistry*, **1998**, 41, 4150-60	8.3	32
109	Conjugation of quinones with natural polyamines: toward an expanded antitrypanosomatid profile. *Journal of Medicinal Chemistry*, **2012**, 55, 10490-500	8.3	31
108	From Companion Diagnostics to Theranostics: A New Avenue for Alzheimer's Disease?. *Journal of Medicinal Chemistry*, **2016**, 59, 7759-70	8.3	31
107	Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2018**, 155, 839-846	6.8	30
106	Parallel synthesis, evaluation, and preliminary structure-activity relationship of 2,5-diamino-1,4-benzoquinones as a novel class of bivalent anti-prion compound. *Journal of Medicinal Chemistry*, **2010**, 53, 8197-201	8.3	30
105	Docking Ligands on Protein Surfaces: The Case Study of Prion Protein. *Journal of Chemical Theory and Computation*, **2009**, 5, 2565-73	6.4	30
104	Small-molecule theranostic probes: a promising future in neurodegenerative diseases. *International Journal of Cell Biology*, **2013**, 2013, 150952	2.6	29
103	Multitarget-directed ligands: innovative chemical probes and therapeutic tools against Alzheimer's disease. *Current Topics in Medicinal Chemistry*, **2011**, 11, 2797-806	3	29
102	Parallel synthesis and cytotoxicity evaluation of a polyamine-quinone conjugates library. *Journal of Medicinal Chemistry*, **2008**, 51, 5463-7	8.3	29
101	In vitro characterization of tripitramine, a polymethylene tetraamine displaying high selectivity and affinity for muscarinic M2 receptors. *British Journal of Pharmacology*, **1995**, 114, 1507-17	8.6	29

100	Structure-activity relationship and site of binding of polyamine derivatives at the nicotinic acetylcholine receptor. *FEBS Journal*, **2000**, 267, 110-20		28
99	Nutritional and Pharmacological Strategies to Regulate Microglial Polarization in Cognitive Aging and Alzheimer's Disease. *Frontiers in Aging Neuroscience*, **2017**, 9, 175	5.3	27
98	Complementary medicinal chemistry-driven strategies toward new antitrypanosomal and antileishmanial lead drug candidates. *FEMS Immunology and Medical Microbiology*, **2010**, 58, 51-60		27
97	The bivalent ligand approach as a tool for improving the in vitro anti-Alzheimer multitarget profile of dimebon. *ChemMedChem*, **2013**, 8, 1276-81	3.7	26
96	Design, synthesis, and biological and crystallographic evaluation of novel inhibitors of Plasmodium falciparum enoyl-ACP-reductase (PfFabI). *Journal of Medicinal Chemistry*, **2013**, 56, 7516-26	8.3	26
95	WB 4101-related compounds. 2. Role of the ethylene chain separating amine and phenoxy units on the affinity for alpha(1)-adrenoreceptor subtypes and 5-HT(1A) receptors. *Journal of Medicinal Chemistry*, **1999**, 42, 4214-24	8.3	26
94	Design, synthesis, and biological activity of prazosin-related antagonists. Role of the piperazine and furan units of prazosin on the selectivity for alpha1-adrenoreceptor subtypes. *Journal of Medicinal Chemistry*, **1998**, 41, 4844-53	8.3	25
93	Progress in acetylcholinesterase inhibitors for Alzheimer's disease: an update. *Expert Opinion on Therapeutic Patents*, **2008**, 18, 387-401	6.8	24
92	Hexahydrochromeno[4,3-b]pyrrole derivatives as acetylcholinesterase inhibitors. *Journal of Medicinal Chemistry*, **2001**, 44, 105-9	8.3	24
91	Design, synthesis, and biological activity of methoctramine-related tetraamines bearing an 11-acetyl-5,11-dihydro-6H-pyrido[2,3-b][1,4] benzodiazepin-6-one moiety: structural requirements for optimum occupancy of muscarinic receptor subtypes as revealed by symmetrical and unsymmetrical polyamines. *Journal of Medicinal Chemistry*, **1994**, 37, 3363-72	8.3	24
90	Approaches for discovering anti-prion compounds: lessons learned and challenges ahead. *Expert Opinion on Drug Discovery*, **2015**, 10, 389-97	6.2	23
89	Location of the polyamine binding site in the vestibule of the nicotinic acetylcholine receptor ion channel. *Journal of Biological Chemistry*, **2001**, 276, 6151-60	5.4	23
88	Sustainable production of pharmaceutical, nutraceutical and bioactive compounds from biomass and waste. *Chemical Society Reviews*, **2021**, 50, 11191-11207	58.5	23
87	A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation. *European Journal of Medicinal Chemistry*, **2012**, 48, 206-13	6.8	22
86	Synthesis of monomeric derivatives to probe memoquin's bivalent interactions. *Journal of Medicinal Chemistry*, **2011**, 54, 8299-304	8.3	22
85	Structure-activity relationships of memoquin: Influence of the chain chirality in the multi-target mechanism of action. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 4312-5	2.9	22
84	A new EGFR inhibitor induces apoptosis in colon cancer cells. *Biochemical and Biophysical Research Communications*, **2007**, 354, 409-13	3.4	21
83	Trypanocidal Activity of Quinoxaline 1,4 Di-N-oxide Derivatives as Trypanothione Reductase Inhibitors. *Molecules*, **2017**, 22,	4.8	20

82	Synthetic polyamines: an overview of their multiple biological activities. *Amino Acids*, **2010**, 38, 383-92	3.5	20
81	Polymethylene tetraamine backbone as template for the development of biologically active polyamines. *Medicinal Research Reviews*, **2003**, 23, 200-33	14.4	19
80	Analysis of the muscarinic receptor subtype mediating inhibition of the neurogenic contractions in rabbit isolated vas deferens by a series of polymethylene tetra-amines. *British Journal of Pharmacology*, **2001**, 132, 1009-16	8.6	19
79	Lewis Acid-Catalyzed Generation of C?C and C?N Bonds on □Deficient Heterocyclic Substrates. *Advanced Synthesis and Catalysis*, **2015**, 357, 185-195	5.6	18
78	Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease. *Journal of Medicinal Chemistry*, **2021**, 64, 4972-4990	8.3	18
77	Repurposing of Drugs Targeting YAP-TEAD Functions. *Cancers*, **2018**, 10,	6.6	18
76	Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity. *European Journal of Medicinal Chemistry*, **2017**, 141, 138-148	6.8	17
75	Quinones bearing non-steroidal anti-inflammatory fragments as multitarget ligands for Alzheimer's disease. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 6254-8	2.9	17
74	Search for selective antagonists at alpha 1-adrenoreceptors: neutral or negative antagonism?. *Il Farmaco*, **1998**, 53, 278-86		17
73	Heterocyclic inhibitors of AChE acylation and peripheral sites. *Il Farmaco*, **2005**, 60, 465-73		17
72	Stereocontrolled transformations of cyclohexadienone derivatives to access stereochemically rich and natural product-inspired architectures. *Organic and Biomolecular Chemistry*, **2020**, 18, 8526-8571	3.9	17
71	N-1,2,3-triazole-isatin derivatives for cholinesterase and □amyloid aggregation inhibition: A comprehensive bioassay study. *Bioorganic Chemistry*, **2020**, 98, 103753	5.1	16
70	Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities. *Medicinal Research Reviews*, **2020**, 40, 2177-2211	14.4	16
69	Synthesis and evaluation of a library of 2,5-bisdiamino-benzoquinone derivatives as probes to modulate protein-protein interactions in prions. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 1866-8	2.9	16
68	Opioid antagonist activity of naltrexone-derived bivalent ligands: importance of a properly oriented molecular scaffold to guide "address" recognition at kappa opioid receptors. *Journal of Medicinal Chemistry*, **1996**, 39, 1816-22	8.3	15
67	Discovery of Sustainable Drugs for Neglected Tropical Diseases: Cashew Nut Shell Liquid (CNSL)-Based Hybrids Target Mitochondrial Function and ATP Production in Trypanosoma brucei. *ChemMedChem*, **2019**, 14, 621-635	3.7	14
66	Neuroregeneration versus neurodegeneration: toward a paradigm shift in Alzheimer's disease drug discovery. *Future Medicinal Chemistry*, **2017**, 9, 995-1013	4.1	14
65	Progress in acetylcholinesterase inhibitors for Alzheimer□ disease. *Expert Opinion on Therapeutic Patents*, **2006**, 16, 811-823	6.8	14

64	Structure-activity relationships of methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. 2. Role of polymethylene chain lengths separating amine functions and of substituents on the terminal nitrogen atoms. *Journal of Medicinal Chemistry*, **2002**, 45, 1860-78	8.3	14
63	A Focused Library of Psychotropic Analogues with Neuroprotective and Neuroregenerative Potential. *ACS Chemical Neuroscience*, **2019**, 10, 279-294	5.7	14
62	Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors. *European Journal of Medicinal Chemistry*, **2019**, 181, 111550	6.8	13
61	Molecular basis for covalent inhibition of glyceraldehyde-3-phosphate dehydrogenase by a 2-phenoxy-1,4-naphthoquinone small molecule. *Chemical Biology and Drug Design*, **2017**, 90, 225-235	2.9	12
60	Solvent- and chromatography-free amination of □deficient nitrogen heterocycles under microwave irradiation. A fast, efficient and green route to 9-aminoacridines, 4-aminoquinolines and 4-aminoquinazolines and its application to the synthesis of the drugs amsacrine and bistacrine. *Tetrahedron*, **2013**, 69, 1024-1030	2.4	12
59	Multi-target-directed ligands as innovative tools to combat trypanosomatid diseases. *Current Topics in Medicinal Chemistry*, **2011**, 11, 2824-33	3	12
58	Sequential virtual screening approach to the identification of small organic molecules as potential BACE-1 inhibitors. *Chemical Biology and Drug Design*, **2011**, 77, 268-71	2.9	12
57	Analogues of prazosin that bear a benextramine-related polyamine backbone exhibit different antagonism toward alpha1-adrenoreceptor subtypes. *Journal of Medicinal Chemistry*, **2001**, 44, 362-71	8.3	12
56	Quinone-amino acid conjugates targeting Leishmania amino acid transporters. *PLoS ONE*, **2014**, 9, e107994	3.7	12
55	Development of a Focused Library of Triazole-Linked Privileged-Structure-Based Conjugates Leading to the Discovery of Novel Phenotypic Hits against Protozoan Parasitic Infections. *ChemMedChem*, **2018**, 13, 678-683	3.7	11
54	Binding profile of benextramine at neuropeptide Y receptor subtypes in rat brain areas. *European Journal of Pharmacology*, **1994**, 265, 93-8	5.3	11
53	Neurodegenerative drug discovery: building on the past, looking to the future. *Future Medicinal Chemistry*, **2017**, 9, 707-709	4.1	10
52	Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease. *ACS Medicinal Chemistry Letters*, **2019**, 10, 671-676	4.3	10
51	Hybrid lipoic acid derivatives to attack prion disease on multiple fronts. *ChemMedChem*, **2011**, 6, 601-5	3.7	10
50	Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform. *SLAS Discovery*, **2019**, 24, 346-361	3.4	9
49	Presynaptic M3 muscarinic cholinoceptors mediate inhibition of excitatory synaptic transmission in area CA1 of rat hippocampus. *Brain Research*, **2015**, 1629, 260-9	3.7	9
48	Structure-activity relationships of methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. 3. Effect of inserting the tetraamine backbone into a macrocyclic structure. *Journal of Medicinal Chemistry*, **2002**, 45, 3286-95	8.3	9
47	Design, synthesis, and biological activity of methoctramine-related polyamines as putative G(i) protein activators. *Journal of Medicinal Chemistry*, **2001**, 44, 4035-8	8.3	9

46	Modulation of prion by small molecules: from monovalent to bivalent and multivalent ligands. *Current Topics in Medicinal Chemistry*, **2013**, 13, 2491-503	3	9
45	Structure-activity relationships and mechanistic studies of novel mitochondria-targeted, leishmanicidal derivatives of the 4-aminostyrylquinoline scaffold. *European Journal of Medicinal Chemistry*, **2019**, 171, 38-53	6.8	8
44	Rational approach to an antiprion compound with a multiple mechanism of action. *Future Medicinal Chemistry*, **2015**, 7, 2113-20	4.1	8
43	Novel multi target-directed ligands targeting 5-HT receptors with in cellulo antioxidant properties as promising leads in Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2019**, 182, 111596	6.8	8
42	Synthesis of new lipoic acid conjugates and evaluation of their free radical scavenging and neuroprotective activities. *Chemical Biology and Drug Design*, **2014**, 83, 688-96	2.9	8
41	Synthesis, muscarinic blocking activity and molecular modeling studies of 4-DAMP-related compounds. *Bioorganic and Medicinal Chemistry*, **1995**, 3, 267-77	3.4	8
40	Multitarget ligands and theranostics: sharpening the medicinal chemistry sword against prion diseases. *Future Medicinal Chemistry*, **2014**, 6, 1017-29	4.1	7
39	Design, synthesis, and biological evaluation of substituted 2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylamine related compounds as fructose-1,6-bisphosphatase inhibitors. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 7846-53	3.4	7
38	Design, synthesis and biological evaluation of ambenonium derivatives as AChE inhibitors. *Il Farmaco*, **2003**, 58, 917-28		7
37	The Mu.Ta.Lig. Chemotheca: A Community-Populated Molecular Database for Multi-Target Ligands Identification and Compound-Repurposing. *Frontiers in Chemistry*, **2018**, 6, 130	5	6
36	Therapeutic Approaches to Prion Diseases. *Progress in Molecular Biology and Translational Science*, **2017**, 150, 433-453	4	6
35	The modulatory role of M2 muscarinic receptor on apomorphine-induced yawning and genital grooming. *Neuroscience Letters*, **2012**, 531, 91-5	3.3	6
34	Multitarget Drug Discovery for Alzheimer's Disease: Triazinones as BACE-1 and GSK-3 Inhibitors. *Angewandte Chemie*, **2015**, 127, 1598-1602	3.6	5
33	Multitargeted Drugs for Treatment of Alzheimer's Disease **2012**, 441-458		5
32	Investigation of the photostability properties of memoquin, a quinone derivative for the treatment of Alzheimer's disease. *Journal of Pharmaceutical and Biomedical Analysis*, **2009**, 50, 164-70	3.5	5
31	Monolithic stationary phase coupled with coulometric detection: development of an ion-pair HPLC method for the analysis of quinone-bearing compounds. *Journal of Separation Science*, **2007**, 30, 2935-42	3.4	5
30	Design, synthesis, and biological evaluation of pirenzepine analogs bearing a 1,2-cyclohexanediamine and perhydroquinoxaline units in exchange for the piperazine ring as antimuscarinics. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 7311-20	3.4	5
29	Novel screening approaches for human prion diseases drug discovery. *Expert Opinion on Drug Discovery*, **2019**, 14, 983-993	6.2	4

28	Binding of polyamine-containing toxins in the vestibule of the nicotinic acetylcholine receptor ion channel. *Il Farmaco*, **2001**, 56, 133-5		4
27	Turning Donepezil into a Multi-Target-Directed Ligand through a Merging Strategy. *ChemMedChem*, **2021**, 16, 187-198	3.7	4
26	In silico/in‐vitro screening and hit evaluation identified new phenothiazine anti-prion derivatives. *European Journal of Medicinal Chemistry*, **2020**, 196, 112295	6.8	3
25	Medicinal Chemistry of Hybrids for Neurodegenerative Diseases **2017**, 259-277		3
24	Chapter 18:Discovery of Multi-Target Agents for Neurological Diseases via Ligand Design. *RSC Drug Discovery Series*, **2012**, 290-315	0.6	3
23	Amyloid Chemical Probes and Theranostics: Steps Toward Personalized Medicine in Neurodegenerative Diseases. *Methods and Principles in Medicinal Chemistry*, **2013**, 211-226	0.4	3
22	Identification of a 2,4-diaminopyrimidine scaffold targeting Trypanosoma brucei pteridine reductase 1 from the LIBRA compound library screening campaign. *European Journal of Medicinal Chemistry*, **2020**, 189, 112047	6.8	3
21	Synthesis and structure-activity relationships of novel arylpiperazines as potent antagonists of α1-adrenoceptor. *European Journal of Medicinal Chemistry*, **2016**, 122, 601-610	6.8	3
20	From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects. *European Journal of Medicinal Chemistry*, **2021**, 225, 113779	6.8	3
19	Design, Synthesis and Structure‐Activity Relationships of a Phenotypic Small Library against Protozoan Infections. *Proceedings (mdpi)*, **2017**, 1, 648	0.3	2
18	A General Protocol for the Solvent- and Catalyst-Free Synthesis of 2-Styrylquinolines under Focused Microwave Irradiation. *Synlett*, **2011**, 2011, 2577-2579	2.2	2
17	Recent advances in the design and synthesis of prazosin derivatives. *Expert Opinion on Drug Discovery*, **2006**, 1, 395-407	6.2	2
16	[4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]-trimethylammonium (McN-A-343)-related compounds. Effect of the butynyl chain inclusion into an aromatic unit on the potency for muscarinic receptors. *Bioorganic and Medicinal Chemistry*, **2000**, 8, 681-9	3.4	2
15	Therapeutic strategies for identifying small molecules against prion diseases.. *Cell and Tissue Research*, **2022**, 1	4.2	2
14	Tackling Neurodegeneration with Multi-target and Theranostic Small Molecules. *Medicinal Chemistry Reviews*, **2015**, 347-356	0.1	2
13	α-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis. *ACS Medicinal Chemistry Letters*, **2020**, 11, 2406-2413	4.3	2
12	Design and In Vitro Study of a Dual Drug-Loaded Delivery System Produced by Electrospinning for the Treatment of Acute Injuries of the Central Nervous System. *Pharmaceutics*, **2021**, 13,	6.4	2
11	Polyamines May Modulate Both G Protein-Coupled Receptors and G Proteins. *Medicinal Chemistry Research*, **2004**, 13, 63-73	2.2	1

10	Phenothiazine-Tacrine Heterodimers: Pursuing Multitarget Directed Approach in Alzheimer's Disease. *ACS Chemical Neuroscience*, **2021**, 12, 1698-1715	5.7	1
9	Sustainable anti-trypanosomatid drugs: An aspirational goal for medicinal chemistry. *Annual Reports in Medicinal Chemistry*, **2019**, 153-176	1.6	1
8	A Different Kind of Medicinal Chemistry Toolbox. *ACS Medicinal Chemistry Letters*, **2020**, 11, 245-248	4.3	0
7	Remembering Marie Curie's legacy. *ChemMedChem*, **2011**, 6, 575-7	3.7	0
6	Discovery of sustainable drugs for Alzheimer's disease: cardanol-derived cholinesterase inhibitors with antioxidant and anti-amyloid properties. *RSC Medicinal Chemistry*, **2021**, 12, 1154-1163	3.5	0
5	Drug Discovery Strategies for the Generation of Multitarget Ligands against Neglected Tropical Diseases. *Methods and Principles in Medicinal Chemistry*, **2017**, 135-159	0.4	
4	Sustainable Multi-Target Drugs for Neglected Tropical Diseases Caused by Trypanosomatids: Dream or Reality?. *Proceedings (mdpi)*, **2017**, 1, 664	0.3	
3	Multitarget Drug Discovery1-7		
2	New Biomass Reagents for the Synthesis of Bioactive Compounds. *Topics in Medicinal Chemistry*, **2021**, 373-389	0.4	
1	Design and synthesis of nature-inspired chromenopyrroles as potential modulators of mitochondrial metabolism. *Medicinal Chemistry Research*, **2021**, 30, 635-646	2.2	